Buchumschlag

Hand–foot skin reaction as a positive prognostic factor in vascular endothelial growth factor receptor‐tyrosine kinase inhibitor treatment

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	I‐Hsin Huang, Po‐Chien Wu, Chun‐Nan Yeh, Ching‐Chi Chi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	British Journal of Pharmacology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Janus kinase inhibitors for the treatment of lichen Sclerosus: A systematic review
von: Chin‐Hsuan Shen, et al.
Veröffentlicht: (2025)

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients
von: Grace Whelan, et al.
Veröffentlicht: (2026)

7,4′‐dimethoxy‐3‐hydroxyflavone, a protease‐activated receptor 4 (PAR4) inhibitor with antioxidant activity, ameliorates diabetic endothelial dysfunction
von: Ju‐Ying Tsai, et al.
Veröffentlicht: (2025)

Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single‐agent fibroblast growth factor receptor‐specific inhibitors in pancreatic cancer
von: Qingxiang Lin, et al.
Veröffentlicht: (2024)

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases
von: Henning Olbrich, et al.
Veröffentlicht: (2026)

Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
von: Siyue Chen, et al.
Veröffentlicht: (2024)

Fatty acid binding protein 3 activates endothelial adhesion of circulating monocytes and impairs endothelial angiogenesis
von: Yen‐Wen Wu, et al.
Veröffentlicht: (2025)

Formulation breakthroughs driving broader tyrosine kinase use
von: Hans Lennernäs, et al.
Veröffentlicht: (2026)

Targeting the tyrosine kinase Src in endothelium attenuates inflammation and atherogenesis induced by disturbed flow
von: Huanyu Ding, et al.
Veröffentlicht: (2024)

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
von: Yuji Kumagai, et al.
Veröffentlicht: (2025)

Inhibition of proline‐rich tyrosine kinase 2 restores cardioprotection by remote ischaemic preconditioning in type 2 diabetes
von: Ralf Erkens, et al.
Veröffentlicht: (2024)

Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database
von: Zeng‐Xiang Zhao, et al.
Veröffentlicht: (2024)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
von: Yue Wu, et al.
Veröffentlicht: (2024)

Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
von: Zhili Jin, et al.
Veröffentlicht: (2026)

The sodium–glucose co‐transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor‐β
von: Ting‐ting Lyu, et al.
Veröffentlicht: (2025)

Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue
von: Kiran Yadav, et al.
Veröffentlicht: (2026)

Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours
von: Yi Sun, et al.
Veröffentlicht: (2024)

Activating transcription factor‐3 orchestrates the modulation of vascular anti‐contractile activity and relaxation by governing the secretion of HDL‐bound sphingosine‐1‐phosphate in perivascular adipose tissue
von: Hsiao‐Fen Li, et al.
Veröffentlicht: (2025)

A p75 neurotrophin receptor‐sparing nerve growth factor protects retinal ganglion cells from neurodegeneration by targeting microglia
von: Laura Latini, et al.
Veröffentlicht: (2024)

2‐Hydroxyl hispolon reverses high glucose‐induced endothelial progenitor cell dysfunction through the PI3K/Akt/eNOS and AMPK/HO‐1 pathways
von: Ta‐Jung Wang, et al.
Veröffentlicht: (2025)

Notoginsenoside‐Fa mitigates vascular endothelial permeability via targeting SUGT1 to stabilize NLRP3 in a resting state
von: Xiao‐Ying Yu, et al.
Veröffentlicht: (2026)

Pharmacological inhibition of the interleukin‐1 receptor‐associated kinase prevents angiotensin II‐induced cardiac remodelling in mice
von: Shreya Jaiswal, et al.
Veröffentlicht: (2026)

Synthesis and evaluation of a novel inhibitor for the α5‐GABA A receptor in the treatment of peripheral neuralgia: Evidence from MD simulation and in vivo studies
von: Yanming Chen, et al.
Veröffentlicht: (2025)

First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment
von: Yue Cheng, et al.
Veröffentlicht: (2025)

Protein tyrosine phosphatases as emerging targets for cancer immunotherapy
von: Zihan Qu, et al.
Veröffentlicht: (2024)

Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis
von: Shichao Xiao, et al.
Veröffentlicht: (2024)

AMPK activation modulates IL‐36‐induced inflammatory responses by regulating IκBζ expression in the skin
von: Yi‐Ting Huang, et al.
Veröffentlicht: (2024)

Role of inflammasomes in endothelial dysfunction
von: Jimin Wu, et al.
Veröffentlicht: (2024)

A novel role for microtubule affinity‐regulating kinases in neuropathic pain
von: Yao‐Qin Shi, et al.
Veröffentlicht: (2024)

Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a critical regulator of inflammatory signalling through toll‐like receptors 4 and 7/8 in murine and human lungs
von: Ian Sayers, et al.
Veröffentlicht: (2024)

Pharmacological treatment with a GABA(A) receptor modulator and a selective serotonin reuptake inhibitor as a mitigation strategy against aircraft noise‐induced cardiovascular and neuronal damage
von: Ivana Kuntić, et al.
Veröffentlicht: (2026)

Rhynchophylline as an agonist of sirtuin 3 ameliorates endothelial dysfunction via antagonizing mitochondrial damage of endothelial progenitor cells
von: Lin Lin, et al.
Veröffentlicht: (2025)

An orally available Cav2.2 calcium channel inhibitor for the treatment of neuropathic pain
von: Janine Kutzsche, et al.
Veröffentlicht: (2024)

The PARP inhibitor rucaparib blocks SARS‐CoV‐2 virus binding to cells and the immune reaction in models of COVID‐19
von: Henrietta Papp, et al.
Veröffentlicht: (2024)

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
von: Mohammad Ghasemi, et al.
Veröffentlicht: (2025)

Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders
von: Eduardo Rivera‐Mancilla, et al.
Veröffentlicht: (2025)

High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction
von: Marcin A. Sowa, et al.
Veröffentlicht: (2025)

Role of protein kinase A and A kinase anchoring proteins in buffering and compartmentation of cAMP signalling in human airway smooth muscle cells
von: Rinzhin T. Sherpa, et al.
Veröffentlicht: (2024)

Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic–ischaemic encephalopathy
von: Elisa Landucci, et al.
Veröffentlicht: (2024)

Targeting acetylated high mobility group box 1 protein (HMGB1) and toll‐like receptor (TLR4) interaction to alleviate hypertension and neuroinflammation in fructose‐fed rats
von: Yu‐Te Lin, et al.
Veröffentlicht: (2024)